Christina Lloyd, SVP and Global Head of Ferring Pharmaceuticals’ Reproductive Medicine and Maternal Health, is responsible for leading and overseeing the strategic planning and direction of all aspects of the company’s core therapeutic focus area.
Prior to joining Ferring, Christina was CEO of Pharmiva, a Sweden-based listed femtech company, She has more than 20 years of experience in management positions in pharmaceutical companies such as Novo Nordisk and also previously served as Ferring as Medical Director between 2002 and 2009. Christina holds a medical degree from the Faculty of Medicine, Lund University and is a specialist in Obstetrics and Gynaecology. She also gained a Medical Business Strategy degree at SIMI Copenhagen and Executive Foundation Lund board degree. In addition, she furthered her leadership and management education at Harvard Business and IMD Business School.
No woman should die while giving birth. Midwives are critical in reducing maternal and neonatal mortality and in improving girls' and women’s reproductive and maternal health worldwide. F...
Why are women still dying from preventable problems during pregnancy and childbirth? Why are women across all disease areas consistently diagnosed later than men? And, why are women exper...
